Navigation Links
Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
Date:1/8/2012

PARSIPPANY, N.J., Jan. 8, 2012 /PRNewswire/ -- Novartis Consumer Health, Inc. (NCH) announced today that it is voluntarily recalling all lots of select bottle packaging configurations of Excedrin® and NoDoz® products with expiry dates of December 20, 2014 or earlier as well as Bufferin® and Gas-X Prevention® products with expiry dates of December 20, 2013 or earlier, in the United States. NCH is taking this action as a precautionary measure because the products may contain stray tablets, capsules, or caplets from other Novartis products, or contain broken or chipped tablets.

The affected bottle sizes are attached to this release. The Novartis Consumer Health Inc. Lincoln, NE facility has voluntarily suspended operations and shipments to accelerate maintenance and other improvement activities at the site.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).

Mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended or receiving an unintended ingredient. This could potentially result in overdose, interaction with other medications a consumer may be taking, or an allergic reaction if the consumer is allergic to the unintended ingredient. NCH is not aware of adverse events reported with the issues leading to the recall.

These over-the-counter products were distributed nationwide to wholesalers and retailers.

Novartis Consumer Health Inc. is notifying its distributors and customers and is arranging for return of all recalled products. Wholesalers and retailers should stop distribution and return the affected product using Novartis Product Return information that is being provided to them.

Consumers that have the product(s) being recalled should stop using the product(s) and contact the Novartis Consumer Relationship Center at 1-888-477-2403 (available Monday-Friday 9 a.m. to 8 p.m. Eastern Time) for information on how to return the affected products and receive a full refund. For more detailed information, consumers should visit our website at www.novartisOTC.com as of January 9, 2012. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these drug products.

Adverse events that may be related to the use of these products may be reported to FDA's MedWatch Adverse Event Reporting Program either online, by regular mail or by fax:

  • Online: www.fda.gov/medwatch/report.htm
  • Regular Mail: use postage-paid FDA form 3500 available at:
    www.fda.gov/MedWatch/getforms.htm.
    Mail to MedWatch, FDA, 5600 Fishers Lane, Rockville, MD  20852-9787
  • Fax: 1-800-FDA-0178
  • These actions announced today, highlight the strong Novartis commitment to a single quality standard for the Novartis Group. The Novartis Group is making the necessary investments and committing the right resources to ensure these are implemented across the entire Novartis Group network. The high quality of Novartis products and operations has been critical to building the Novartis Group reputation over the past 15 years. Novartis Group is committed to ensuring the highest standard for patients who rely on our products and medicines.

    Novartis Consumer Health Inc. plans to gradually resume operations at its Lincoln, NE site following implementation of planned improvements and in agreement with the FDA. The Novartis Consumer Health Inc. Lincoln, NE facility produces a variety of products mainly for the US market with annual sales value of less than 2% of Novartis Group sales. At this stage, it is not possible to determine when the plant will resume full operations and the full financial impact of these events. NCH will take a one-time charge currently estimated at USD 120 million in the fourth quarter of 2011, relating to the recalls and improvement work at the Lincoln, NE facility.

    Novartis commitment to qualityThe Novartis Group is fully committed to ensuring the quality, safety and integrity of its products. All Novartis Group companies have a clear commitment to patients and Health Authorities to ensure high quality standards for all our products and services. Novartis Group companies stand behind the safety and efficacy of their products, and are fully committed to maintaining high quality standards at all production sites in the US and around the world. All Novartis Group products are subjected to strict manufacturing, testing and monitoring standards. Where they fall outside the standards, Novartis Group companies take actions to correct the issue and may recall products as a precaution.

    DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "potential," "will," "committed," "commitment," "plans," or similar expressions, or by express or implied discussions regarding the potential length of the shutdown of our Lincoln, NE production facility, regarding the potential for any further regulatory actions at the Lincoln, NE production facility, regarding the potential for any further quality issues arising at any additional Novartis manufacturing facilities, or regarding the potential financial impact of the Lincoln, NE facility shutdown. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that our Lincoln, NE production facility will reopen at any particular time. Nor can there be any guarantee that actions described in this release will be the only regulatory actions required at the Lincoln, NE facility.  Neither can there be any guarantee that further quality issues will not arise at any additional Novartis Group manufacturing facilities.  Nor can there be any guarantee as to the potential financial impact on Novartis resulting from the shutdown of the Lincoln, NE production facility. In particular, management's expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected manufacturing issues, including unexpected inabilities to satisfy regulators' requirements for the reopening of the Lincoln, NE production facility; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    About NovartisNovartis Group provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

    Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

    Novartis Media Relations 

     Julie MasowNovartis Corporation

    +1 212 830 2465 (direct)

    +1 862 579 8456 (mobile)

    julie.masow@novartis.com

     

    Pamela McKinlayNovartis Consumer Health, Inc.

    +1 973 503 7337(direct)

    +1 862 221 0151(mobile)

    pamela.mckinlay@novartis.com

     

    e-mail: us.mediarelations@novartis.com Milicent BrooksNovartis Consumer Health, Inc.

    +1 973 503 7483(direct)

    +1 973 479 2078 (mobile)

    milicent.brooks@novartis.com

     For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
    For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.MaterialMaterial descriptionUPC CodeUCC CodeNDC CodeQuantity Returned100007332

    Bufferin® Extra Strength Tablets 130CT 

    300672065131

    10300672065138

    0067206513

     100007330

    Bufferin® Extra Strength Tablets 39CT 

    300672065391

    10300672065398

    0067206539

     100007776

    Bufferin® Low Dose Tablets 130CT

    300676424132

    10300676424139

    0067642413

     100007345

    Bufferin® Regular Strength Tablets 130CT 

    300672063137

    10300672063134

    0067206313

     100008631

    Excedrin® Back & Body Caplets 100CT Account Specific

    300676238920

    10300676238927

    0067623891

     100008076

    Excedrin® Back & Body Caplets 100CT Account Specific No Carton

    300676238944

    10300676238941

    0067623894

     100008075

    Excedrin® Back & Body Caplets 100CT New Label

    300676238913

    10300676238910

    0067623891

     100008073

    Excedrin® Back & Body Caplets 24CT New Label

    300676238241

    10300676238248

    0067623824

     100008074

    Excedrin® Back & Body Caplets 50CT New Label

    300676238500

    10300676238507

    0067623850

     100008627

    Excedrin® Extra Strength Caplets 100CT Account Specific

    300672000927

    10300672000924

    0067200091

     100005995

    Excedrin® Extra Strength Caplets 100CT Account Specific

    300672000941

    10300672000948

    0067200094

     100008027

    Excedrin® Extra Strength Caplets 100CT Account Specific

    300672000941

    10300672000948

    0067200094

     100008026

    Excedrin® Extra Strength Caplets 100CT Account Specific

    300672000910

    10300672000917

    0067200091

     100003160

    Excedrin® Extra Strength Caplets 100CT

    300672000910

    10300672000917

    0067200091

     100007201

    Excedrin® Extra Strength Caplets 125CT Bonus Pack

    300672000835

    10300672000832

    0067200083

     100008434

    Excedrin® Extra Strength Caplets 125CT Bonus Pack Account Specific

    300672000842

    10300672000849

    0067200084

     100008455

    Excedrin® Extra Strength Caplets 125CT New Carton

    300672000866

    10300672000863

    0067200086

     100009008

    Excedrin® Extra Strength  Caplets 24+6CT Bonus Pack

    300672000309

    10300672000306

    0067200030

     100003157

    Excedrin® Extra Strength  Caplets 24CT

    300672000248

    10300672000245

    0067200024

     100008024

    Excedrin® Extra Strength  Caplets 24CT New Label

    300672000248

    10300672000245

    0067200024

     100004485

    Excedrin® Extra Strength  Caplets 250CT No Carton

    300672000071

    10300672000078

    0067200007

     100008033

    Excedrin® Extra Strength  Caplets 250CT No Carton New Label

    300672000071

    10300672000078

    0067200007

     100004868

    Excedrin® Extra Strength  Caplets 250CT Special Inner

    300672000774

    10300672000771

    0067200077

     100008029

    Excedrin® Extra Strength  Caplets 250CT New Label

    300672000774

    10300672000771

    0067200077

     100008635

    Excedrin® Extra Strength  Caplets 300CT Bonus Pack

    300672000552

    10300672000559

    0067200055

     100008025

    Excedrin® Extra Strength  Caplets 50CT New Label

    300672000507

    10300672000504

    0067200050

     100003158

    Excedrin® Extra Strength  Caplets 50S

    300672000507

    10300672000504

    0067200050

     100007982

    Excedrin® Extra Strength  Express Gel Caps 20CT New Label

    300676270203

    10300676270200

    0067627020

     100007987

    Excedrin® Extra Strength  Express Gel Caps 40CT New Label

    300676270401

    10300676270408

    0067627040

     100008630

    Excedrin® Extra Strength  Express Gel Caps 80CT Account Specific

    300676270814

    10300676270811

    0067627080

     100007988

    Excedrin® Extra Strength  Express Gel Caps 80CT 

    300676270807

    10300676270804

    0067627080

     100007989

    Excedrin® Extra Strength  Express Gel Caps 80CT Account Specific

    300676270944

    10300676270941

    0067627094

     100008037

    Excedrin® Extra Strength  Gel Tablets 24CT 

    300672021243

    10300672021240

    0067202124

     100004674

    Excedrin® Extra Strength  Tablets 100CT Special Inner

    300672030917

    10300672030914

    0067203091

     100008626

    Excedrin® Extra Strength  Tablets 100CT Account Specific

    300672030931

    10300672030938

    0067203091

     100008016

    Excedrin® Extra Strength  Tablets 100CT Account Specific

    300672030948

    10300672030945

    0067203094

     100008010

    Excedrin® Extra Strength  Tablets 100CT New Label

    300672030917

    10300672030914

    0067203091

     100007200

    Excedrin® Extra Strength  Tablets 125CT Bonus Pack

    300672030832

    10300672030839

    0067203083

     100008460

    Excedrin® Extra Strength  Tablets 125CT Bonus Pack New Carton

    300672030863

    10300672030860

    0067203086

     100008022

    Excedrin® Extra Strength  Tablets 200CT New Label

    300672030924

    10300672030921

    0067203092

     100009062

    Excedrin® Extra Strength  Tablets 24+6CT Bonus Pack

    300672030306

    10300672030303

    0067203030

     100003181

    Excedrin® Extra Strength  Tablets 24CT

    300672030245

    10300672030242

    0067203024

     100008008

    Excedrin® Extra Strength  Tablets 24CT New Label

    300672030245

    10300672030242

    0067203024

     100008807

    Excedrin® Extra Strength  Tablets 250+50CT Bonus Pack 

    300672030573

    10300672030570

    0067203055

     100004173

    Excedrin® Extra Strength  Tablets 250CT No Carton

    300672030078

    10300672030075

    0067203007

     100008031

    Excedrin® Extra Strength  Tablets 250CT No Carton New Label

    300672030078

    10300672030075

    0067203007

     100004869

    Excedrin® Extra Strength  Tablets 250CT Special Inners

    300672030771

    10300672030778

    0067203077

     100008019

    Excedrin® Extra Strength  Tablets 250CT New Label

    300672030771

    10300672030778

    0067203077

     100007470

    Excedrin® Extra Strength  Tablets 300CT New Carton

    300672030337

    10300672030310

    0067203033

     100008472

    Excedrin® Extra Strength  Tablets 300CT Club Tray

    300672030337

    10300672030310

    0067203033

     100008020

    Excedrin® Extra Strength  Tablets 300CT New Label

    300672030337

    10300672030310

    0067203033

     100003134

    Excedrin® Extra Strength  Tablets 300S

    300672030337

    10300672030334

    0067203033

     100003186

    Excedrin® Extra Strength  Tablets 50CT

    300672030504

    10300672030501

    0067203050

     100008009

    Excedrin® Extra Strength  Tablets 50CT New Label

    300672030504

    10300672030501

    0067203050

     100006967

    Excedrin® Extra Strength  Tablets 8CT

    300672030085

    10300672030082

    0067203008

     100008007

    Excedrin® Extra Strength  Tablets 8CT New Label

    300672030085

    10300672030082

    0067203008

     100007967

    Excedrin® Migraine  Express Gel Caplets 20CT New Label

    300676341200

    10300676341207

    0067634120

     100003178

    Excedrin® Migraine Caplets 100CT

    300672039910

    10300672039917

    0067203991

     100005998

    Excedrin® Migraine Caplets 100CT Account Specific

    300672039941

    10300672039948

    0067203994

     100008087

    Excedrin® Migraine Caplets 100CT Account Specific No Carton

    300672039941

    10300672039948

    0067203994

     100008656

    Excedrin® Migraine Caplets 100CT Account Specific

    300672043917

    10300672043914

    0067203991

     100008086

    Excedrin® Migraine Caplets 100CT New Label

    300672039910

    10300672039917

    0067203991

     100008443

    Excedrin® Migraine Caplets 125CT Bonus Pack No Carton

    300672039842

    10300672039849

    0067203984

     100008461

    Excedrin® Migraine Caplets 125CT Bonus Pack New Carton

    300672039866

    10300672039863

    0067203986

     100007215

    Excedrin® Migraine Caplets 125CT Bonus Pack

    300672039835

    10300672039832

    0067203983

     100008090

    Excedrin® Migraine Caplets 200CT New Label

    300672039927

    10300672039924

    0067203992

     100009016

    Excedrin® Migraine Caplets 24+6CT Bonus Pack

    300672039309

    10300672039306

    0067203930

     100003182

    Excedrin® Migraine Caplets 24CT

    300672039248

    10300672039245

    0067203924

     100008084

    Excedrin® Migraine Caplets 24CT New Label

    300672039248

    10300672039245

    0067203924

     100008809

    Excedrin® Migraine Caplets 250+50CT Bonus Pack

    300672039576

    10300672039573

    0067203955

     100004174

    Excedrin® Migraine Caplets 250CT No Carton

    300672039071

    10300672039078

    0067203907

     100008093

    Excedrin® Migraine Caplets 250CT No Carton New Label

    300672039071

    10300672039078

    0067203907

     100004870

    Excedrin® Migraine Caplets 250CT Special Inners

    300672039774

    10300672039771

    0067203977

     100008091

    Excedrin® Migraine Caplets 250CT New Label

    300672039774

    10300672039771

    0067203977

     100003121

    Excedrin® Migraine Caplets 300CT

    300672039330

    10300672039337

    0067203933

     100007469

    Excedrin® Migraine Caplets 300CT New Carton

    300672039330

    10300672039313

    0067203933

     100008092

    Excedrin® Migraine Caplets 300CT New Label

    300672039330

    10300672039313

    0067203933

     100008471

    Excedrin® Migraine Caplets 300CT Club Tray

    300672039330

    10300672039313

    0067203933

     100008085

    Excedrin® Migraine Caplets 50CT New Label

    300672039507

    10300672039504

    0067203950

     100003185

    Excedrin® Migraine Caplets 50CT 

    300672039507

    10300672039504

    0067203950

     100008079

    Excedrin® Migraine Caplets 8CT New Label

    300672039088

    10300672039085

    0067203908

     100008015

    Excedrin® Migraine Gel  Tablets 160CT

    300672035165

    10300672035162

    0067203516

     100004681

    Excedrin® Migraine Gel Tablets 100CT Special Inner

    300672035912

    10300672035919

    0067203591

     100008096

    Excedrin® Migraine Gel Tablets 100CT New Label

    300672035912

    10300672035919

    0067203591

     100008657

    Excedrin® Migraine Gel Tablets 100CT Account Specific

    300672044914

    10300672044911

    0067203591

     100008094

    Excedrin® Migraine Gel Tablets 24CT - New Label

    300672035240

    10300672035247

    0067203524

     100008819

    Excedrin® Migraine Gel Tablets 2X50CT

    300672035936

    10300672035933

    0067203593

     100008095

    Excedrin® Migraine Gel Tablets 50CT New Label

    300672035509

    10300672035506

    0067203550

     100004675

    Excedrin® Migraine Tablets 100CT Special Inner

    300672037916

    10300672037913

    0067203791

     100008082

    Excedrin® Migraine Tablets 100CT New Label

    300672037916

    10300672037913

    0067203791

     100008437

    Excedrin® Migraine Tablets 125CT Bonus Pack

    300672037831

    10300672037838

    0067203783

     100009094

    Excedrin® Migraine Tablets 24+6CT Bonus Pack

    300672037305

    10300672037302

    0067203730

     100003174

    Excedrin® Migraine Tablets 24CT

    300672037244

    10300672037241

    0067203724

     100008080

    Excedrin® Migraine Tablets 24CT New Label

    300672037244

    10300672037241

    0067203724

     100004872

    Excedrin® Migraine Tablets 250CT Special Inner

    300672037770

    10300672037777

    0067203777

     100008083

    Excedrin® Migraine Tablets 250CT New Label

    300672037770

    10300672037777

    0067203777

     100003173

    Excedrin® Migraine Tablets 50CT

    300672037503

    10300672037500

    0067203750

     100008081

    Excedrin® Migraine Tablets 50CT New Label

    300672037503

    10300672037500

    0067203750

     100008049

    Excedrin® PM Caplets 100CT New Label

    300672055910

    10300672055917

    0067205591

     100008459

    Excedrin® PM Caplets 125CT Bonus Pack New Carton

    300672055866

    10300672055863

    0067205586

     100008047

    Excedrin® PM Caplets 24CT New Label

    300672055248

    10300672055245

    0067205524

     100008048

    Excedrin® PM Caplets 50CT New Label

    300672055507

    10300672055504

    0067205550

     100007146

    Excedrin® PM Express Gel Caplets 20CT 

    300676405209

    10300676405206

    0067640520

     100008632

    Excedrin® PM Express Gel Caplets 80CT Account Specific

    300676405810

    10300676405817

    0067640580

     100007202

    Excedrin® PM Express Gel Caplets 80CT No Carton

    300676409801

    10300676409808

    0067640980

     100007148

    Excedrin® PM Express Gel Caplets 80CT New Label

    300676405803

    10300676405800

    0067640580

     100008629

    Excedrin® PM Tablets 100CT Account Specific

    300672053923

    10300672053920

    0067205391

     100008065

    Excedrin® PM Tablets 100CT Account Specific No Carton

    300672053947

    10300672053944

    0067205394

     100008064

    Excedrin® PM Tablets 100CT New Label

    300672053916

    10300672053913

    0067205391

     100008449

    Excedrin® PM Tablets 125CT Bonus Pack

    300672053831

    10300672053838

    0067205383

     100009095

    Excedrin® PM Tablets 24+6CT Bonus Pack

    300672053305

    10300672053302

    0067205330

     100008051

    Excedrin® PM Tablets 24CT New Label

    300672053244

    10300672053241

    0067205324

     100008063

    Excedrin® PM Tablets 50CT New Label

    300672053503

    10300672053500

    0067205350

     100008046

    Excedrin® PM Tablets 8CT New Label

    300672053084

    10300672053081

    0067205308

     100008040

    Excedrin® Sinus Headache Caplets 24CT New Label

    300672062246

    10300672062243

    0067206224

     100004691

    Excedrin® Tension Headache Caplets 100CT Special Inner

    300672045911

    10300672045918

    0067204591

     100006001

    Excedrin® Tension Headache Caplets 100CT Account Specific No Carton

    300672045942

    10300672045949

    0067204594

     100008057

    Excedrin® Tension Headache Caplets 100CT Account Specific No Carton New Label

    300672045942

    10300672045949

    0067204594

     100008628

    Excedrin® Tension Headache Caplets 100CT Account Specific 

    300672045959

    10300672045956

    0067204591

     100008056

    Excedrin® Tension Headache Caplets 100CT New Label

    300672045911

    10300672045918

    0067204591

     100008442

    Excedrin® Tension Headache Caplets 125CT Bonus Pack

    300672045836

    10300672045833

    0067204583

     100008453

    Excedrin® Tension Headache Caplets 125CT Bonus Pack No Carton

    300672045843

    10300672045840

    0067204584

     100009007

    Excedrin® Tension Headache Caplets 24+6CT Bonus Pack

    300672045300

    10300672045307

    0067204530

     100004689

    Excedrin® Tension Headache Caplets 24CT Special Inner

    300672045249

    10300672045246

    0067204524

     100008068

    Excedrin® Tension Headache Caplets 24CT New Label

    300672045249

    10300672045246

    0067204524

     100003209

    Excedrin® Tension Headache Caplets 250CT

    300672045775

    10300672045772

    0067204577

     100004406

    Excedrin® Tension Headache Caplets 250CT No Carton

    300672045072

    10300672045079

    0067204507

     100004690

    Excedrin® Tension Headache Caplets 50CT Special Inner

    300672045508

    10300672045505

    0067204550

     100008069

    Excedrin® Tension Headache Caplets 50CT New Label

    300672045508

    10300672045505

    0067204550

     100007978

    Excedrin® Tension Headache Express Gel Caplets 20CT 

    300676272207

    10300676272204

    0067627220

     100007979

    Excedrin® Tension Headache Express Gel Caplets 40CT 

    300676272405

    10300676272402

    0067627240

     100007981

    Excedrin® Tension Headache Express Gel Caplets 80CT Account Specific 

    300676272948

    10300676272945

    0067627294

     100007980

    Excedrin® Tension Headache Express Gel Caplets 80CT 

    300676272801

    10300676272808

    0067627280

     100008060

    Excedrin® Tension Headache Gel Tablets 24CT New Label

    300672050243

    10300672050240

    0067205024

     100007153

    Gas-X® Prevention® Caplets 20CT

    300433005208

    10300433005205

    N/A

     100007154

    Gas-X® Prevention® Caplets 50CT

    300433005505

    10300433005502

    N/A

     100004719

    NoDoz® Maximum Strength Caplets 16CT

    300672070166

    10300672070163

    0067207016

     100008716

    NoDoz® Maximum Strength Caplets 16CT New Graphic

    300672070166

    10300672070163

    0067207016

     100004720

    NoDoz® Maximum Strength Caplets 36CT

    300672070364

    10300672070361

    0067207036

     100008715

    NoDoz® Maximum Strength Caplets 36CT New Graphic

    300672070364

    10300672070361

    0067207036

     100004721

    NoDoz® Maximum Strength Caplets 60CT

    300672070609

    10300672070606

    0067207060

     100008717

    NoDoz® Maximum Strength Caplets 60CT New Graphic

    300672070609

    10300672070606

    0067207060

      


    '/>"/>

    SOURCE Novartis Consumer Health, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
    2. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
    3. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
    4. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
    5. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
    6. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
    7. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
    8. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
    9. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
    10. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
    11. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
    (Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
    (Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
    (Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
    (Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
    (Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
    Breaking Medicine News(10 mins):